Depresif Bozukluklar
Synopsis
This study comprehensively examines the classification of depressive disorders according to DSM-5, focusing particularly on the diagnostic criteria, epidemiology, risk factors, and etiology of Major Depressive Disorder (MDD). MDD is defined by the presence of at least five symptoms—such as depressed mood, loss of interest, weight and sleep changes, psychomotor agitation or retardation, fatigue, feelings of guilt, concentration difficulty, and suicidal ideation—over a two-week period. With a lifetime prevalence ranging from 1.5% to 19%, it is twice as common in women and constitutes the leading cause of disability worldwide. Genetic vulnerability, adverse early childhood experiences, and chronic medical conditions serve as primary risk factors. Its pathophysiology involves a reduction in monoamine neurotransmitters (serotonin, norepinephrine, dopamine), HPA axis hyperactivity, elevated cortisol, and pro-inflammatory cytokines. Treatment utilizes psychotherapy for mild cases and pharmacotherapy for moderate to severe cases. First-line agents include SSRIs, agomelatin, bupropion, mirtazapine, and vortioxetine, whereas treatment-resistant cases warrant augmentation strategies with atypical antipsychotics or lithium. Additionally, Electroconvulsive Therapy (ECT) along with CBT, interpersonal, and psychodynamic psychotherapies constitute essential elements of management.
References
Lam RW, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: introduction and methods. Can J Psychiatry. 2016;61(9):506-509.
American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA):APA; 2013.
McIntyre RS, Schaffer A, Beaulieu S. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid conditions. Ann Clin Psychiatry. 2012;24:2-3.
Eom CS, Lee HK, Ye S, et al. Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis. J Bone Miner Res. 2012;27:1186-1195.
Kudlow PA, McIntyre RS, Lam RW. Early switching strategies in antidepressant non-responders: current evidence and future research directions. CNS Drugs. 2014;28:601-609.
Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry. 2015;76:e487-e498.